Bleeding Complications After Use of Novel Oral Anticoagulants in Patients Undergoing Cardiac Surgery

Annals of Thoracic Surgery

Volumn 105, Issue 3, 2018, Pages 702-708

  Hassan, Kambiz ^a   Bayer, Nikolai ^a   Schlingloff, Friederike ^a   Oberhoffer, Martin ^a   Wohlmuth, Peter ^b   Schmoeckel, Michael ^a   Geidel, Stephan ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b Asklepios ProResearch Institute   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; DESMOPRESSIN; FIBRINOGEN; FRESH FROZEN PLASMA; PROTHROMBIN; RIVAROXABAN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; AORTIC CLAMPING; ARTICLE; ATRIAL FIBRILLATION; CARDIOPULMONARY BYPASS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEEP VEIN THROMBOSIS; ERYTHROCYTE TRANSFUSION; EUROSCORE; FEMALE; HEART ATRIUM THROMBOSIS; HEART DEATH; HEART LEFT ATRIUM; HEART LEFT VENTRICLE; HEART VALVE SURGERY; HEART VENTRICLE THROMBOSIS; HUMAN; INTENSIVE CARE UNIT; INTESTINE ISCHEMIA; KIDNEY FUNCTION; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OPEN HEART SURGERY; OPERATIVE BLOOD LOSS; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REOPERATION; RETINA ARTERY OCCLUSION; RETROSPECTIVE STUDY; SEPSIS; SURGICAL INFECTION; SURGICAL MORTALITY; SURGICAL PATIENT; THORACOTOMY; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT WITHDRAWAL; BLOOD TRANSFUSION; COMPLICATION; HEART DISEASE; HEART SURGERY; INTENSIVE CARE; PATHOLOGY; RISK ASSESSMENT;

AGED; ANTICOAGULANTS; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; CRITICAL CARE; DABIGATRAN; FEMALE; HEART DISEASES; HUMANS; LENGTH OF STAY; MALE; POSTOPERATIVE HEMORRHAGE; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RIVAROXABAN;

EID: 85041557637     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2017.11.066     Document Type: Article

References (15)

1. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al., for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
2. Patel, M.R., Mahaffey, K.W., Garg, J., et al., for the ROCKET-AF Steering Committee and Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
3. Granger, C.B., Alexander, J.H., McMurray, J.J., et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
4. Lip, G.Y., Lane, D.A., Matching the NOAC to the patient: remember the modifiable bleeding risk factors. J Am Coll Cardiol 66 (2015), 2282–2284.
5. Caldeira, D., Barra, M., Ferreira, A., et al. Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. Aliment Pharmacol Ther 42 (2015), 1239–1249.
6. Steiner, T., Diringer, M., Rosand, J., Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and open questions. Stroke 37 (2006), 256–262.
7. Geidel, S., Krause, K., Boczor, S., et al. Ablation surgery in patients with persistent atrial fibrillation: an 8-year clinical experience. J Thorac Cardiovasc Surg 141 (2011), 377–382.
8. Schlingloff, F., Oberhoffer, M., Quasdorff, I., et al. Oral anticoagulation after successful atrial fibrillation ablation surgery. Is it necessary?. Ann Thorac Surg 101 (2016), 1471–1476.
9. Decousus, H., Tapson, V.F., Bergmann, J.F., et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE Investigators. Chest 139 (2011), 10–13.
10. Heidbuchel, H., Verhamme, P., Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17 (2015), 1467–1507.
11. Burnett, A.E., Mahan, C.E., Vazquez, S.R., Oertel, L.B., Garcia, D.A., Ansell, J., Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 41 (2016), 206–232.
12. Hernandez, I., Baik, S.H., Pinera, A., Zhang, Y., Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 175 (2015), 18–24.
13. Heidbuchel, H., Verhamme, P., Alings, M., et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15 (2013), 625–651.
14. Angheloiu, G.O., Gugiu, G.B., Ruse, C., et al. Ticagrelor removal from human blood. J Am Coll Cardiol 2 (2017), 135–145.
15. Angheloiu GO, van Ryan J, Goss AM. Removal of dabigatran using sorbent hemadsorption. Presented at Scientific Sessions of the American Heart Association, November 7–11, 2015, Orlando, Florida.